Literature DB >> 8335426

Effect of food on pravastatin pharmacokinetics and pharmacodynamics.

H Y Pan1, A R DeVault, D Brescia, D A Willard, M E McGovern, D B Whigan, E Ivashkiv.   

Abstract

The pharmacokinetics and pharmacodynamics of pravastatin 20 mg administered twice daily when taken with or one hour before meals were evaluated in 24 hypercholesterolemic men in an 8-week, open-label, randomized, two-way crossover study. The bioavailability of pravastatin was reduced significantly (p < or = 0.001) when it was taken with meals (AUC dropped 31% and Cmax dropped 49%), and mean Tmax increased 50% (p < or = 0.01). The mean elimination t1/2 was unaffected by taking pravastatin with food. However, reductions in mean total cholesterol and low density lipoprotein cholesterol were identical whether pravastatin was given with or before meals. In both treatment groups, total cholesterol and low-density lipoprotein cholesterol were significantly reduced from baseline (p < 0.001). These results indicate that although the bioavailability of pravastatin is reduced when taken with meals, the lipid-lowering efficacy of pravastatin is not altered. It can be concluded that pravastatin can be ingested without regard to meal time.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8335426

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  16 in total

Review 1.  Food-drug interactions.

Authors:  Lars E Schmidt; Kim Dalhoff
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Predicting effect of food on extent of drug absorption based on physicochemical properties.

Authors:  Chong-Hui Gu; Hua Li; Jaquan Levons; Kimberley Lentz; Rajesh B Gandhi; Krishnaswamy Raghavan; Ronald L Smith
Journal:  Pharm Res       Date:  2007-03-24       Impact factor: 4.200

3.  Steady-state pharmacokinetics of pravastatin in children with familial hypercholesterolaemia.

Authors:  Heleen E Wiersma; Albert Wiegman; Richard P Koopmans; Henk D Bakker; John J P Kastelein; Chris J van Boxtel
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

Review 4.  Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.

Authors:  J P Desager; Y Horsmans
Journal:  Clin Pharmacokinet       Date:  1996-11       Impact factor: 6.447

5.  Functional Consequences of Pravastatin Isomerization on OATP1B1-Mediated Transport.

Authors:  Jonathan B Wagner; Melissa Ruggiero; J Steven Leeder; Bruno Hagenbuch
Journal:  Drug Metab Dispos       Date:  2020-09-05       Impact factor: 3.922

Review 6.  Pediatric Statin Administration: Navigating a Frontier with Limited Data.

Authors:  Jonathan Wagner; Susan M Abdel-Rahman
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Sep-Oct

Review 7.  Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.

Authors:  David Williams; John Feely
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 8.  Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events.

Authors:  T Hatanaka
Journal:  Clin Pharmacokinet       Date:  2000-12       Impact factor: 6.447

Review 9.  Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.

Authors:  H Lennernäs; G Fager
Journal:  Clin Pharmacokinet       Date:  1997-05       Impact factor: 6.447

Review 10.  Pravastatin: a review of its use in elderly patients.

Authors:  Lynne M Bang; Karen L Goa
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.